0001019056-20-000441.txt : 20200729
0001019056-20-000441.hdr.sgml : 20200729
20200729214057
ACCESSION NUMBER: 0001019056-20-000441
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200727
FILED AS OF DATE: 20200729
DATE AS OF CHANGE: 20200729
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: White Marvin L
CENTRAL INDEX KEY: 0001493324
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37746
FILM NUMBER: 201058901
MAIL ADDRESS:
STREET 1: 2273 RESEARCH BLVD
STREET 2: SUITE 400
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aptevo Therapeutics Inc.
CENTRAL INDEX KEY: 0001671584
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 811567056
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2401 4TH AVE.
STREET 2: SUITE 1050
CITY: SEATTLE
STATE: WA
ZIP: 98121
BUSINESS PHONE: 206-838-0500
MAIL ADDRESS:
STREET 1: 2401 4TH AVE.
STREET 2: SUITE 1050
CITY: SEATTLE
STATE: WA
ZIP: 98121
4
1
white.xml
X0306
4
2020-07-27
0
0001671584
Aptevo Therapeutics Inc.
APVO
0001493324
White Marvin L
C/O APTEVO THERAPEUTICS INC.
2401 4TH AVENUE, SUITE 1050
SEATTLE
WA
98121
1
1
0
0
CEO and President
Stock Option (right to buy)
25.20
2020-07-27
4
D
0
2545
D
2021-05-22
Common Stock
2545
0
D
Stock Option (right to buy)
41.16
2020-07-27
4
D
0
14319
D
2026-08-03
Common Stock
14319
0
D
Stock Option (right to buy)
27.44
2020-07-27
4
D
0
5414
D
2027-02-24
Common Stock
5414
0
D
Stock Option (right to buy)
30.10
2020-07-27
4
D
0
5414
D
2027-06-01
Common Stock
5414
0
D
Stock Option (right to buy)
43.82
2020-07-27
4
D
0
10828
D
2028-03-09
Common Stock
10828
0
D
Stock Option (right to buy)
21.28
2020-07-27
4
D
0
10828
D
2029-02-28
Common Stock
10828
0
D
Stock Option (right to buy)
8.56
2020-07-27
4
A
0
16625
A
2030-07-26
Common Stock
16625
16625
D
Stock Option (right to buy)
8.56
2020-07-27
4
A
0
4813
A
2030-07-26
Common Stock
4813
4813
D
Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020.
The stock option award vested on May 22, 2017. This award was originally part of a grant from Emergent BioSolutions Inc. ("Emergent") dated May 22, 2014 of which two-thirds were vested at the time of conversion to issuer's equity pool.
In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4.
This stock option award vested over three years, and the final one-third vested on August 3, 2019.
This stock option award vested over three years, and the final one-third vested on February 24, 2020.
This stock option award vested over three years, and the final one-third vested on June 1, 2020.
This stock option award provides for vesting in three approximately equal annual installments beginning on March 9, 2019. Prior to July 27, 2020, all but 3,609 shares of the issuer's common stock underlying this stock option had vested.
This stock option award provides for vesting in three approximately equal annual installments beginning on February 28, 2020. Prior to July 27, 2020, all but 7,219 shares of the issuer's common stock underlying this stock option had vested.
These options vest in full on the one year anniversary of the date of grant.
These options will vest in three approximately equal annual installments beginning on the one year anniversary of the date of grant.
/s/ Carl A. Valenstein, attorney-in-fact
2020-07-29